May 30, 2018 08:12 AM EDT
R&D
Pharma

FDA moves Sage’s post­par­tum de­pres­sion drug brex­anolone in­to reg­u­la­tors’ busy pri­or­i­ty lane

John Carroll

Editor & Founder

The FDA’s pri­or­i­ty re­view path­way is get­ting a work­out.

Reg­u­la­tors agreed to give Sage Ther­a­peu­tics $SAGE a quick 6-month re­view for IV …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Up­dat­ed: Trump ad­min­is­tra­tion halts more than $750M in funds for Mod­er­na’s bird flu vac­cine

The fate of Mod­er­na’s next-gen Covid shot looms large af­ter a flur­ry of pol­i­cy changes

No­vo Nordisk ‘strong­ly’ urges against phar­ma tar­iffs as com­ments flood in

A new dawn for psy­che­delics? Com­pass could be the first to find out

Weeks af­ter TIG­IT fail, iTeos de­cides to wind down

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times